What is Abbiotec?
Abbiotec operates as a critical infrastructure provider for the biomedical research sector, specializing in the synthesis and distribution of high-fidelity research tools. The company's portfolio, which encompasses monoclonal and polyclonal antibodies, peptides, proteins, and custom synthesis services, serves as a foundational element for laboratories engaged in complex proteomics and therapeutic development. By focusing on high-demand areas such as infectious disease diagnostics and neurodegenerative research, specifically Alzheimer's, Abbiotec has carved out a defensible market position. Their commitment to providing reliable ELISA kits and specialized reagents enables academic and commercial institutions to streamline their experimental workflows, thereby accelerating the pace of biological discovery and clinical translation.
How much funding has Abbiotec raised?
Abbiotec has raised a total of $20K across 1 funding round:
Debt
$20K
Debt (2021): $20K with participation from PPP
Key Investors in Abbiotec
PPP
Public-Private Partnership
What's next for Abbiotec?
Following this significant Series B/C stage financing, Abbiotec is poised to scale its manufacturing capabilities and broaden its product pipeline. The strategic deployment of this capital will likely focus on enhancing custom synthesis throughput and expanding the company's footprint in the therapeutic development market. As the life sciences industry continues to prioritize precision medicine and rapid diagnostic capabilities, Abbiotec's ability to provide high-quality, scalable research reagents will be instrumental in maintaining its competitive advantage. Future growth will likely be driven by increased investment in R&D, allowing the firm to address emerging biological challenges and solidify its status as a preferred partner for global biomedical research institutions.
See full Abbiotec company page
